vs
CBAK Energy Technology, Inc.（CBAT）とMESA LABORATORIES INC（MLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
MESA LABORATORIES INCの直近四半期売上が大きい（$65.1M vs $58.8M、CBAK Energy Technology, Inc.の約1.1倍）。MESA LABORATORIES INCの純利益率が高く（5.6% vs -12.5%、差は18.1%）。CBAK Energy Technology, Inc.の前年同期比売上増加率が高い（131.8% vs 3.6%）。MESA LABORATORIES INCの直近四半期フリーキャッシュフローが多い（$18.0M vs $16.1M）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs -0.0%）
CBAKエナジーテクノロジーはリチウムイオン電池の研究開発・製造・販売を行うグローバルサプライヤーで、高性能セル、モジュール、バッテリーパックを提供しています。電気自動車、定置型エネルギー貯蔵システム、民生用電子機器分野を主な顧客層とし、中国を拠点に世界中に顧客を持っています。
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
CBAT vs MLAB — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $58.8M | $65.1M |
| 純利益 | $-7.4M | $3.6M |
| 粗利率 | 7.3% | 64.2% |
| 営業利益率 | -13.6% | 12.2% |
| 純利益率 | -12.5% | 5.6% |
| 売上前年比 | 131.8% | 3.6% |
| 純利益前年比 | -63.6% | 316.6% |
| EPS（希薄化後） | $-0.08 | $0.65 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $58.8M | $65.1M | ||
| Q3 25 | $60.9M | $60.7M | ||
| Q2 25 | $40.5M | $59.5M | ||
| Q1 25 | $34.9M | $62.1M | ||
| Q4 24 | $25.4M | $62.8M | ||
| Q3 24 | $44.6M | $57.8M | ||
| Q2 24 | $47.8M | $58.2M | ||
| Q1 24 | $58.8M | $58.9M |
| Q4 25 | $-7.4M | $3.6M | ||
| Q3 25 | $2.7M | $2.5M | ||
| Q2 25 | $-3.1M | $4.7M | ||
| Q1 25 | $-1.6M | $-7.1M | ||
| Q4 24 | $-4.5M | $-1.7M | ||
| Q3 24 | $17.6K | $3.4M | ||
| Q2 24 | $6.4M | $3.4M | ||
| Q1 24 | $9.8M | $-254.6M |
| Q4 25 | 7.3% | 64.2% | ||
| Q3 25 | 8.0% | 61.5% | ||
| Q2 25 | 11.0% | 62.0% | ||
| Q1 25 | 13.7% | 61.8% | ||
| Q4 24 | 13.1% | 63.3% | ||
| Q3 24 | 15.6% | 61.3% | ||
| Q2 24 | 26.6% | 64.0% | ||
| Q1 24 | 31.9% | 62.1% |
| Q4 25 | -13.6% | 12.2% | ||
| Q3 25 | -6.6% | 7.8% | ||
| Q2 25 | -8.7% | 5.1% | ||
| Q1 25 | -8.2% | 2.4% | ||
| Q4 24 | -26.0% | 9.2% | ||
| Q3 24 | -1.9% | 6.1% | ||
| Q2 24 | 12.4% | 9.6% | ||
| Q1 24 | 17.4% | -460.6% |
| Q4 25 | -12.5% | 5.6% | ||
| Q3 25 | 4.4% | 4.1% | ||
| Q2 25 | -7.6% | 8.0% | ||
| Q1 25 | -4.5% | -11.4% | ||
| Q4 24 | -17.8% | -2.7% | ||
| Q3 24 | 0.0% | 5.9% | ||
| Q2 24 | 13.5% | 5.8% | ||
| Q1 24 | 16.7% | -432.2% |
| Q4 25 | $-0.08 | $0.65 | ||
| Q3 25 | $0.03 | $0.45 | ||
| Q2 25 | $-0.03 | $0.85 | ||
| Q1 25 | $-0.02 | $-1.30 | ||
| Q4 24 | $-0.05 | $-0.31 | ||
| Q3 24 | $0.00 | $0.63 | ||
| Q2 24 | $0.07 | $0.62 | ||
| Q1 24 | $0.11 | $-47.26 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $8.3M | $29.0M |
| 総負債低いほど良い | $4.1M | $68.4M |
| 株主資本純資産 | $112.7M | $186.7M |
| 総資産 | $426.2M | $434.8M |
| 負債/資本比率低いほどレバレッジが低い | 0.04× | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $8.3M | $29.0M | ||
| Q3 25 | $10.5M | $20.4M | ||
| Q2 25 | $45.7M | $21.3M | ||
| Q1 25 | $9.6M | $27.3M | ||
| Q4 24 | $11.0M | $27.3M | ||
| Q3 24 | $24.2M | $24.3M | ||
| Q2 24 | $44.1M | $28.5M | ||
| Q1 24 | $23.8M | $28.2M |
| Q4 25 | $4.1M | $68.4M | ||
| Q3 25 | $4.8M | $69.4M | ||
| Q2 25 | $4.9M | $70.3M | ||
| Q1 25 | $4.1M | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
| Q4 25 | $112.7M | $186.7M | ||
| Q3 25 | $121.4M | $178.5M | ||
| Q2 25 | $118.2M | $172.5M | ||
| Q1 25 | $120.8M | $159.8M | ||
| Q4 24 | $121.7M | $155.2M | ||
| Q3 24 | $131.2M | $161.5M | ||
| Q2 24 | $126.6M | $150.7M | ||
| Q1 24 | $120.9M | $145.4M |
| Q4 25 | $426.2M | $434.8M | ||
| Q3 25 | $363.9M | $430.4M | ||
| Q2 25 | $333.1M | $435.7M | ||
| Q1 25 | $311.5M | $433.3M | ||
| Q4 24 | $302.2M | $433.3M | ||
| Q3 24 | $293.5M | $454.1M | ||
| Q2 24 | $279.6M | $440.4M | ||
| Q1 24 | $286.5M | $446.8M |
| Q4 25 | 0.04× | 0.37× | ||
| Q3 25 | 0.04× | 0.39× | ||
| Q2 25 | 0.04× | 0.41× | ||
| Q1 25 | 0.03× | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $29.8M | $18.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $16.1M | $18.0M |
| FCFマージンFCF / 売上 | 27.3% | 27.7% |
| 設備投資強度設備投資 / 売上 | 23.4% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 5.17× |
| 直近12ヶ月FCF直近4四半期 | $3.9M | $37.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.8M | $18.8M | ||
| Q3 25 | $14.6M | $8.2M | ||
| Q2 25 | $13.8M | $1.9M | ||
| Q1 25 | $-9.6M | $12.7M | ||
| Q4 24 | $9.6M | $18.1M | ||
| Q3 24 | $19.7M | $5.3M | ||
| Q2 24 | $2.9M | $10.7M | ||
| Q1 24 | $7.4M | $12.9M |
| Q4 25 | $16.1M | $18.0M | ||
| Q3 25 | $6.0M | $7.1M | ||
| Q2 25 | $4.1M | $884.0K | ||
| Q1 25 | $-22.3M | $11.9M | ||
| Q4 24 | $3.9M | $17.3M | ||
| Q3 24 | $16.5M | $3.5M | ||
| Q2 24 | $2.5M | $9.9M | ||
| Q1 24 | $-454.0K | $12.3M |
| Q4 25 | 27.3% | 27.7% | ||
| Q3 25 | 9.9% | 11.7% | ||
| Q2 25 | 10.2% | 1.5% | ||
| Q1 25 | -63.9% | 19.2% | ||
| Q4 24 | 15.5% | 27.6% | ||
| Q3 24 | 37.1% | 6.0% | ||
| Q2 24 | 5.2% | 16.9% | ||
| Q1 24 | -0.8% | 21.0% |
| Q4 25 | 23.4% | 1.1% | ||
| Q3 25 | 14.1% | 1.8% | ||
| Q2 25 | 23.8% | 1.7% | ||
| Q1 25 | 36.3% | 1.2% | ||
| Q4 24 | 22.5% | 1.3% | ||
| Q3 24 | 7.0% | 3.1% | ||
| Q2 24 | 0.9% | 1.5% | ||
| Q1 24 | 13.4% | 0.9% |
| Q4 25 | — | 5.17× | ||
| Q3 25 | 5.51× | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1115.72× | 1.54× | ||
| Q2 24 | 0.46× | 3.17× | ||
| Q1 24 | 0.76× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CBAT
| Manufacturing Lithium Batteries | $28.0M | 48% |
| Residential Energy Supply And Uninterruptable Supplies | $17.8M | 30% |
| Light Electric Vehicles | $12.9M | 22% |
| Precursor | $108.0K | 0% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
